Home > Morie A Gertz, ASH 2018 – Hereditary TTR Amyloidosis and the NEURO-TTR Study
Haematology

Morie A Gertz, ASH 2018 – Hereditary TTR Amyloidosis and the NEURO-TTR Study

Published Online: December 10th 2018

We spoke to Professor Morie Getz at ASH 2018 about the current unmet needs in treatment of hereditary TTR amyloidosis, antisense technology, inotersen and the NEURO-TTR study.

Questions:
1. What is hereditary TTR amyloidosis and what are the unmet needs in its treatment? (0:10)
2. Could you tell us a little about antisense technology and the mechanism of action of inotersen? (1:13)
3. What have been the major efficacy and safety findings of the NEURO-TTR study to date? (2:10)
4. What were the conclusions of the recent long-term update from the open-label extension of NEURO-TTR? (2:58)
5. What are the next steps in the clinical development of inotersen? (3:41)

Speaker’s disclosures: Morie A Gertz has received honoraria from Akcea and Ionis.

Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, December 1–4, 2018.

Related Videos In Haematology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar